The medical community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s exhibiting significant promise in clinical trials for managing obesity. Unlike some available weight loss treatments, retatrutide appears to provide a greater substantial decrease in body size and improve metabolic health, particu